Serum proteins play an important role in binding to many drugs, including antibiotics. In general, serum proteins decrease the free fraction of antibiotic available to eliminate bacteria, since only the non-protein bound molecules are pharmacologically active. The proteins involved in this sequestration are mainly human serum albumin (HSA), the most abundant serum protein (4% w/v), α-1-acid glycoprotein (AGP), and γ-globulin (4, 6, 11) .
Currently, most of the reports of the inhibitory effects of serum proteins on antibiotics are derived from in vitro studies employing the minimal inhibitory concentration (MIC) method (8, 10) or time killing curves (16) . These reports correlate well with in vivo data (13) and are useful to evaluate the potential of a new drug candidate. However, it is also necessary to rapidly and precisely characterize how a molecule binds to serum proteins in term of affinity constants to drive the synthesis of new and more efficient analogs. A variety of physical techniques have been proposed to measure protein binding. The most classical are ultracentrifugation (10) or dialysis (7, 10) but other alternative techniques have been used like circular dichroism (1) , and extrinsic fluorescence (15) . More recently, surface plasmon resonance was proposed as a medium-to highthroughput alternative to evaluate the kinetics of relatively lipophylic drugs binding to human serum proteins in real time (14) .
Antibiotics are characterized by a relatively high hydrophilicity as compared to other drug classes. Consequently, antibiotics have lower affinities for serum proteins. Because the development of fast analytical methods that allow the measurement of antibiotic-serum protein interaction kinetics with a small amount of sample is desirable, we have evaluated if SPR can measure low affinities, and how SPR can be used to pre-screen rapidly libraries of antibiotic candidates for their propensity to bind to serum proteins.
MATERIAL AND METHODS
Bacterial strains, antimicrobial agents and media. S. aureus reference strains CIP 76.25 (ATCC 25923) was used. S. aureus was grown, subcultured, and quantified in MuellerHinton broth (MHB) and on Mueller-Hinton agar (Difco Laboratories, Detroit, MI, USA). The following antimicrobial agents belonging to different antibiotic classes were selected.
Rifampicin, vancomycin, minocycline, fusidic acid, novobiocin, lincomycin, ofloxacin, cefotaxime, erythromycin, and the nonantibiotic molecule warfarin, used as control, were purchased from Sigma-Aldrich (St Louis, MO, USA). Depending on the experiment, the MHB medium was supplemented with human serum albumin, α−1-acid glycoprotein from human plasma, or γ-globulin from human blood (Sigma-Aldrich, St Louis, MO, USA).
Surface plasmon resonance experiments. SPR experiments were performed at 25 °C using a BIACORE 3000 apparatus (GE Healthcare, Biacore AB, Uppsala, Sweden).
Procedure for protein immobilization: HSA diluted to 40 µg/mL in 10 mM acetate buffer, pH 5.2, was immobilized on CM5 sensor chips using amine-coupling chemistry. The surface was blocked with 1 M ethanolamine, pH 8.0, and washed with three 30 s-pulses of 50 mM NaOH to remove free HSA. Human Immunoglobulin G (γ-globulins) (Sigma-Aldrich, St Louis, MO, USA) was immobilized on flow cell 3 using the same method. PDEA-modified AGP was immobilized on flow cell 4 using a standard surface thiol coupling procedure (9) . The immobilization level ranges from 9000 to 12000 RU (Resonance Unit) for γ-globulins and HSA, and 7000-10000 RU for AGP. 
RESULTS
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Ranking of the antibiotic-serum protein interactions. Nine antibiotics with different physicochemical properties were used to set up an experimental protocol to determine HSA, AGP and γ-globulins binding levels. Some of these have been previously characterized by microbiological methods but, in most the cases, the binding kinetics and affinities are unknown.
HSA, AGP and γ-globulins differ in their molecular weight and their capacity to coat the surface of the sensor chip, which impairs the direct comparison of the binding responses. An average coating of 9000-12000 RU was observed, and we have normalized the response to an average level of 10000 RU. Equilibrium responses were collected in randomized duplicates for the 9 antibiotics at 250 µM. The association and dissociation were achieved rapidly, and no regeneration of the surface was necessary. At this concentration, all of the compounds gave measurable responses. We show that novobiocin and fusidic acid gave a higher response on HSA than on AGP (Fig. 1) . Vancomycin, erythromycin and lincomycin, to a lesser extent, gave a higher binding level for AGP than for HSA. Cefotaxime, minocycline, and rifampicin bind to HSA and AGP at quite similar levels. The non-antibiotic molecule warfarin was used as a control throughout the experiments. Ranking experiments on γ-globulins were less conclusive, since all the drugs exhibit low binding responses (< 5) at a maximum coating level.
Antimicrobial experiments were performed to compare the SPR ranking with the inhibitory effects of serum, HSA, AGP, and γ-globulin. HSA, AGP, and γ-globulins were used at a concentration equivalent to their respective serum concentrations, though these purified proteins are unlikely to give a response strictly comparable to the one expected in a more complex environment. The strongest HSA binders, novobiocin and fusidic acid, were the most affected by the presence of HSA in the culture broth; a 256-fold increase in the MICs was observed in the presence of 4 % HSA and a 1000-fold increase in presence of serum (Table 1) . Cefotaxime and minocycline demonstrate almost identical data for biosensor response in the presence of the three proteins and the effect of the proteins on antimcrobial activity against Staphylococcus aureus is comparable. However their values for percentage binding to serum taken from the literature rank them as high binders. This discrepancy can potentially be explained by differences in the technique used for this measurements (ie: ultracentrifugation, dialysis…) or the origin of the serum.
The strongest AGP binders (novobiocin, fusidic acid, vancomycin, lincomycin, and erythromycin) were also the most affected by the presence of AGP, with a two fold increase in (Table 1) is almost uniform according to the SPR data and is limited to a 2-fold increase in the MIC ratio.
Kinetics and fraction of sites occupied
SPR is well suited to determine how many binding sites are involved in the interactions between drugs and serum proteins. HSA is known to have two main sites of drug binding, and warfarin is a well-characterized HSA ligand that binds preferentially to site I (3). Frostell-Karlsson and colleagues (5) and Rich et al. (14) used warfarin as a model molecule to validate a SPR method for drug/HSA binding constant determination from dose-response measurements. We expanded the same procedure for antibiotic molecules to determine the fraction of sites occupied on HSA and AGP.
The range of drug concentrations that allows occupancy of 0.5 to 2 sites/protein molecule is listed in the Table 2 for the nine antibiotics. Novobiocin is a high HSA binder, occupying up to 2 sites at 180 µg/ml. Fusidic acid and rifampicin occupied 1.5 sites at 215 and 320 µg/ml, respectively.
Since most of the drugs occupied more than one binding site on HSA, they generate rather complex binding kinetics for a concentration range from 0.1 µg/ml to 250 µg/ml. This prevented us from evaluating the affinities for all the sites. We have only estimated the Kd for the first site from the binding curve. They range from 12-150 µM. On AGP, the fraction of sites occupied is less than one for all the drugs (data not shown).
The binding profiles of the different drugs are informative on their properties and 3 of them are shown as an example to illustrate our purpose in Fig. 2 . Rifampicin, gave a linear dose-response binding curve over a wide range of concentration (1-300 µg/ml) and does not saturate HSA (not more then 20 RU binding at 300 µg/ml). Novobiocin and fusidic acid the highest HSA binder in the SPR ranking experiment also showed non saturating binding profiles between 0.1 and 300 µg/ml but we have observed respectively 2 to 4 fold more binding at 300 µg/ml.
DISCUSSION
The technique presented here was successfully used to evaluate the propensity of reference antibiotics for HSA, AGP, and γ-globulin. Serum proteins control the availability and the distribution of most of the drugs. HSA interacts principally with acidic molecules (6) like fusidic
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acid or novobiocin, while AGP is a major target for the binding of a wide variety of basic and neutral drugs (17) . By binding to HSA, many hydrophobic drugs with low solubility can be transported to reach their target tissues effectively. A decrease in the concentration of molecules readily available to interact with the true target protein results in the decrease of the antimicrobial activity of the molecule. This is why the evaluation of the binding of antibiotics to serum proteins is a critical aspect in the development of this category of drugs.
In our assay, the relatively hydrophilic antibiotics tested have lower affinities for serum proteins then most of the other classes of drugs tested by SPR (5, 14) . However, we show that the technique is robust enough to test this drug family. The antibiotics with the strongest ability to physically interact with serum proteins are the most affected by the presence of serum in MIC assays (our data and (2, 10)). As expected, HSA is the most abundant plasma protein, which accounts for approximately 60% of the total proteins, and is the major contributor to the binding of these reference antibiotics. The binding of drugs to multiple sites on HSA is well documented in the literature (6) . This correlated with the complex binding kinetics observed in our experiments, and prevented us from evaluating the affinities for all the sites. However, the occupancy of the drug binding sites by an antibiotic at a given concentration can be readily compared to the Cmax of the antibiotic. In the case of erythromycin, a concentration of about 150 µg/ml is necessary to occupy 50% of the HSA sites. However, the Cmax of this antibiotic does not exceed a few µg/ml (2). We conclude that the binding occurs in a concentration range far higher then the concentration reached in the serum. Alternatively, one molecule of novobiocin binds one molecule of HSA at a concentration of 60 µg/ml, and its Cmax is in same range of concentration (2), which makes the observation directly relevant for the pharmacologist. In conclusion, SPR is not a substitute to classical techniques since the binding of a drug to a single purified protein like HSA does not always mimic the behavior of the same drug on serum.
However HSA by far is the major contributor to these interactions and SPR discriminates efficiently between low and high HSA-antibiotic binders. These could help to rapidly and automatically prescreen larger libraries of new antibiotic candidates. The concentration dependent binding of rifampicin ( ), fusidic acid ( ), novobiocin (■) on HSA was followed by SPR. The binding response is presented on the left axe, and the fraction sites occupied on the protein on the right. (2, 10) 
